KTLA

Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'

Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side effects from Alzheimer's disease treatments To accelerate partnering efforts with global pharmaceutical ...
Morningstar

Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'

Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments Highlighted clinical cases that ...
Yahoo Finance

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis Advanced analysis of neuroimaging features associated with ...
The Victoria Advocate

Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'

Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD Company accelerates partnerships with global ...
The Korea Herald

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

This clearance marks Neurophet's third FDA 510(k) clearance, following Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET image quantitative analysis ...
Kosmo

Neurophet Secures FDA 510(k) Clearance for “Neurophet AQUA AD Plus,” Marking Its Third U.S. Regulatory Milestone

Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet’s leadership in AI-based Alzheimer’s disease imaging analysis Advanced analysis of neuroimaging features associated with ...